SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after announcing a new licensing agreement with Pfizer for its Matrix-M adjuvant technology, which the community sees as a major validation for its platform. Investors are keenly discussing the potential for a substantial short squeeze, fueled by high short interest and expectations of more partnerships for Matrix-M as a multi-billion dollar asset.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing significant activity as President Trump's announcement of a Greenland "framework" and the suspension of EU tariffs fueled a rapid market rebound. Traders are actively discussing the "TACO trade," where initial geopolitical uncertainty quickly reversed, leaving bears burned and reinforcing the "buy the dip" strategy amidst perceived market manipulation. This volatility underscores how headline-driven events continue to create dramatic swings in market sentiment.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

The Metals Company (TMC) is generating significant buzz as investors keenly follow recent U.S. regulatory updates, including streamlined deep-sea mining permit processes and an upcoming Congressional hearing featuring TMC's CEO. The community anticipates a major breakout, driven by increasing recognition of deep-sea minerals as a national security priority and the potential for expedited commercial recovery.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market attention following recent Saudi FDA approval for its Anktiva lung cancer treatment and ongoing dialogue with the FDA for a bladder cancer resubmission. The community is intensely focused on the escalating cost to borrow and diminishing share availability, widely anticipating a massive short squeeze that could propel the stock higher. Many investors are actively "loading the boat," confident in the company's cancer immunotherapy advancements and viewing current market dynamics as a temporary battle against "trapped" short sellers.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively discussed amidst evolving geopolitical developments surrounding Greenland's rare earth mineral rights, particularly following recent statements from former President Trump and upcoming business updates. Investors are closely watching for definitive outcomes, with many anticipating a significant boost from any potential deal securing U.S. access to Greenland's vast critical metal deposits, despite notable short-term volatility and accusations of market manipulation.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending sharply higher after President Trump announced a "framework" deal with NATO regarding Greenland and unexpectedly reversed course on potential new tariffs against Europe. This geopolitical de-escalation is sparking a significant market rally, with many traders labeling it a "TACO" (Trump Always Chickens Out) trade as market fears rapidly dissipate. Community discussion highlights the immediate bullish reaction, while some question the broader implications of such swift policy reversals on market stability.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is trending following news that its subsidiary, Lucid Diagnostics, has secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, broadening access to precancer screening. This development, combined with the stock's low float, is fueling intense community discussion about a potential short squeeze and substantial upside, although some express concerns about possible dilution.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending due to a significant partnership with Primary Digital Infrastructure for a massive AI data center campus in West Texas, coupled with a key acquisition. The community is actively discussing strong price action and anticipating an imminent announcement regarding a hyperscaler tenant, fueling speculation of continued upward momentum and a potential short squeeze within the burgeoning AI infrastructure sector.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing a notable surge, primarily fueled by promising 5-year clinical data for its personalized cancer vaccine in collaboration with Merck and recent global regulatory submissions for its seasonal flu vaccine. The community is actively discussing the company's improved financial outlook and strategic shift towards its diverse mRNA pipeline beyond prior vaccine products. This reevaluation is amplified by a significant short interest, with many anticipating continued momentum in the broader biotech sector.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is currently trending amidst significant investor apprehension, fueled by reports of a bondholder lawsuit concerning a 2025 offering and growing concerns over its substantial debt funding ambitious AI infrastructure projects. Community sentiment is largely bearish, questioning management's strategy and the long-term profitability of AI commitments, particularly those linked to OpenAI. However, a contrasting view points to Oracle's considerable cloud backlog and speculative upcoming deals, like a potential TikTok transaction, as reasons for a significant rebound from recent lows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

iBio, Inc. (IBIO) Reports Q1 Loss

iBio (IBIO) delivered earnings and revenue surprises of -57.14% and 0.00%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Keros Therapeutics, Inc. (KROS) Reports Q3 Loss, Tops Revenue Estimates

Keros Therapeutics (KROS) delivered earnings and revenue surprises of +83.78% and +86.04%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Exelixis (EXEL) Beats Q3 Earnings and Revenue Estimates

Exelixis (EXEL) delivered earnings and revenue surprises of +14.71% and +1.49%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Despite Fast-paced Momentum, Bionano Genomics (BNGO) Is Still a Bargain Stock

Bionano Genomics (BNGO) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.

Bionano Genomics (BNGO) Is Attractively Priced Despite Fast-paced Momentum

Bionano Genomics (BNGO) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

Bionano Genomics triggered&nbsp;heavy retail chatter on Wednesday after the company provided a full-year 2025 revenue forecast in the range of $26 million to $30 million, falling short of the consensus estimate of $30.33 million.The company's second-quarter (Q2) revenue projection fell between $6.3 million and $6.8 million, while analysts expected $7.01 million.Bionano disclosed $6.5 million in revenue for Q1 2025, which surpassed the consensus figure of $6.25 million.&nbsp;The gross margin percentage increased to 46% compared to 32% from the previous year.&nbsp;GAAP operating expenses plunged by 66% to $11.4 million, while non-GAAP costs reduced by 65% to $8.5 million because of downsizing and restructuring product development efforts.Bionano shares closed 5.3% lower at $3.74 on Tuesday but rebounded 20.3% to $4.50 in after-hours trading.CEO Erik Holmlin noted that the March quarter represented the first period for executing their new strategy, which targets routine users of OGM systems and VIA software.&nbsp;The company reported stable utilization rates and increased consumables sales to routine users, which led to an extended cash runway until the first quarter of 2026.Bionano's Q1 sales of nanochannel array flowcells reached 6,994 units, representing a 15% decrease from the previous year, although existing customer sales expanded by 1% when accounting for new account volumes.&nbsp;The company added nine OGM systems to its network in the quarter, which increased its total system count to 379 from 347 at the same time last year.Bionano confirmed its plans to deploy between 15 and 20 new OGM systems in 2025.On Stocktwits, retail sentiment was ‘extremely bearish’ amid a&nbsp;6,300% surge in 24-hour message volume.One user warned of a potential 35% drop in the stock, while another described the company as obsolete and predicted a decline toward zero.<stembedurl>https://stocktwits.com/Jewkee/message/614685155</stembedurl><stembedurl>https://stocktwits.com/v92/message/614672774</stembedurl>The stock has declined 75.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bionano Genomics (NASDAQ: BNGO) logo seen displayed on a smartphone with an Artificial intelligence (AI) chip and symbol in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Bionano Genomics Retail Mood Turns ‘Extremely Bearish’ Amid Revenue Guidance Shortfall

Despite a 46% gross margin improvement and significant cost cuts, the stock fell over 5% on Wednesday before jumping 20% in after-hours trading

Equity

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Bionano Genomics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.36	--	--	N/A
Q3 '25	-$2.08	-$2.49	-20.00%	MISSED
Q2 '25	-$2.66	-$2.00	24.72%	BEAT
Q1 '25	-$3.02	--	--	N/A
Q4 '24	-$5.90	--	--	N/A

BNGO
Bionano Genomics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest BNGO News

BNGOBionano Genomics Inc